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Abstract: Differentiation of blood cells is one of the most complex processes in the body. It is
regulated by the action of transcription factors in time and space which creates a specific signaling
network. In the hematopoietic signaling system, Notch is one of the main regulators of lymphocyte
development. The aim of this study was to get insight into the regulation of Notch signalization
and the influence of poly(ADP-ribose)polymerase (PARP) activity on this process in three leukemia
cell lines obtained from B and T cells. PARP1 is an enzyme involved in posttranslational protein
modification and chromatin structure changes. B and T leukemia cells were treated with Notch
and PARP inhibitors, alone or in combination, for a prolonged period. The cells did not show cell
proliferation arrest or apoptosis. Analysis of gene and protein expression set involved in Notch and
PARP pathways revealed increase in JAGGED1 expression after PARP1 inhibition in B cell lines and
changes in Ikaros family members in both B and T cell lines after γ-secretase inhibition. These data
indicate that Notch and PARP inhibition, although not inducing differentiation in leukemia cells,
induce changes in signaling circuits and chromatin modelling factors.
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1. Introduction
Today great efforts are being undertaken in the development of differentiation programs for
cancer and leukemia cells to stop their proliferation and to change their biology. There are certain
types of leukemia cells which can be differentiated, but still the majority of tumors are refractive
to differentiation cues [1]. In this study, we investigated the possibility of cellular reprogramming
by prolonged inactivation of NOTCH and PARP pathways in different leukemia cell lines of B and
T origin.
Notch pathway is an important signaling pathway regulating differentiation in various tissues.
Notch is a transmembrane receptor which binds ligands DELTA-LIKE and JAGGED, present on the
membrane of neighboring cells. The pathway activation depends on a specific Notch receptor cleavage
by γ-secretase, after ligand binding. Released Notch intracellular domain (NICD) can recruit activation
complex to the promoter sequence RBPJ present in target genes. Although having only a small number
of signaling elements, this pathway is modulated by numerous factors, such as expression of inhibitors,
cooperation with other signaling pathways, promoters’ chromatin structure and presence of cofactors
that determine the set of genes expressed in targeted cells [2,3]. In hematopoietic cells, its main role is
to direct lymphocytes toward T cell line, although it also has a role in certain steps of B cell and other
blood cell differentiation. Its constitutive activation was found to drive tumorigenesis in different
types of leukemia, such as T cell acute lymphoblastic leukemia (T-ALL) and B cell chronic lymphocytic
leukemia (B-CLL) [2,4,5].
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To see whether chromatin structure and modification of signaling molecules can influence Notch
signaling, in this work, we treated cells with poly(ADPribose)polymerase (PARP1) inhibitor. PARP1
is an enzyme involved in the process of polyADPribosylation, addition of polyADPribose chains
on proteins and chromatin. This process is triggered by DNA damage, and its purpose is to change
the chromatin structure and recruit enzymes for DNA damage repair. On the other side, more and
more other functions were found to be executed by PARP1, such as transcription factors’ modification,
participation in stem cell establishment and differentiation process [6]. PARP1 was found to influence
Notch signaling by modifying transcriptional complex of Notch target HES1 and downstream gene
expression [7]. The interaction between HES1 and PARP1 was also found in B-ALL cells where HES1
expression induced PARP1 activation and led to apoptosis [8]. These interactions appeared to be
cell-type specific.
In this article, we describe the changes that appeared in three model hematopoietic cell lines after
long-term treatment with Notch and PARP inhibitors to see whether it is possible to change the cell
fate. PARP inhibition was included as potential chromatin and transcription modifier. Results show
that all cell lines analyzed retained proliferation and viability. We observed an immediate decrease
in expression of typical Notch target proteins in T-ALL Jurkat cells. Prolonged treatment with Notch
inhibitor led to decrease in Ikaros family proteins in different leukemia cell lines, in a cell-specific way.
PARP inhibition also influenced the expression of NOTCH ligands. These data indicate that Notch and
PARP inhibition induce changes in signaling circuits and chromatin modelling factors regardless of
typical Notch pathway activity and cell type.
2. Materials and Methods
2.1. Cell Lines and Cell Culture
Cell lines were obtained from the German Cell Culture Collection (DSMZ): Jurkat, human T cell
leukemia cells, CLL, chronic lymphocytic leukemia cells and 697, human B cell precursor leukemia
cells. The cells were periodically tested for the presence of mycoplasma with EZ-PCR Mycoplasma
Test Kit (Biological Industry, Beit Haemek, Israel). CLL cell line was established from Epstein-Barr
virus (EBV) immortalized neoplastic lymphocytes and the infection was classified as latent. Cells
were cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with
10% FCS (Sigma-Aldrich, St. Louis, MO, USA), treated with Notch inhibitor DAPT (N-[N-(3,5-
Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) (Sigma-Aldrich, St. Louis, MO, USA)
and PARP inhibitor PJ-34 (N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino) acetamide
hydrochloride) (Sigma-Aldrich, St. Louis, MO, USA). Control samples were treated with DMSO
(Sigma-Aldrich, St. Louis, MO, USA).
2.2. Growth Curve and Treatment
For growth curve, cells were seeded in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 10% FCS at the optimum cell concentration of about 4 × 105 cells/mL. Cells were
counted, passaged and treated with inhibitors every other day. Cell viability was determined by
counting cells under the light microscope after Trypan blue exclusion staining. The treatment cycle
and downstream experiments were repeated for each cell type at least twice.
2.3. RNA Isolation and Preparation of cDNA
Total RNA was extracted using TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA) according
to the manufacturer’s instructions. Reverse transcription of isolated RNA was done using random
hexamers and Primescript (TaKaRa), according to manufacturer’s protocol.
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2.4. Quantitative Real-Time PCR
Real-time quantitative PCR (qRT-PCR) was performed using 7500 Fast Real-Time PCR System
(Applied Biosystems, Waltham, MA, USA) and GoTaq qPCR Master Mix (Promega, Madison,
WI, USA). All primers were designed using publicly available software’s primer3plus [9] and IDT
PrimerQuest Tool [10]. The following primers were used: HPRT (forward: CTTTGCTGACCTGCTGGATT,
reverse: TCCCCTGTTGACTGGTCATT), HES1 (forward: GAGCACAGAAAGTCATCAAAGC, reverse:
CCGCGAGCTATCTTTCTTCA), NOTCH1 (forward: ACTCGTTCACCTGCCTGTGT, reverse: CACAC
CAGTGCACAAGGTTC), NOTCH2 (forward: CTGGCAACACGCATTACT, reverse: GGCACTCATC
CACTTCATAC), JAGGED1 (forward: GACTCATCAGCCGTGTCTCA, reverse: TGGGGAACAC
TCACACTCAA), PARP1 (forward: TGGAAATGCTTGACAACCTG, reverse: CATTGTGTGTGGTT
GCATGA), PARG1 (forward: TCCAGAATGGGAAAGATGTG, reverse: CTCAGCATAGCCTGTGT
ATTC), IKZF1-Ikaros (forward: CACTCCGTTGGTAAACCTC, reverse: CCTATCTTGCACAGGTCT
TC), IKZF3-Aiolos (forward: GAAGAGCCTGAAATCCCTTAC, reverse: CCAGTATGGCTTCGCTTA
TG), c-MYC (forward: CTGCTTAGACGCTGGATTT, reverse: CTCCTCGTCGCAGTAGAAA), EBNA2
(forward: TTCCACCTATGCCATTACCC, reverse: GCCTTGAGTCTTAGAGGGTT).
Expression of HPRT gene was used as an endogenous control for normalization. Efficacy of PCR
reaction was calculated from the slope of the amplification curve in the exponential phase, by using
linear regression software (LinRegPCR 2014.x) and was higher than 90%. Product specificity was
determined by amplicon melting curve. All significant changes were confirmed on two or three
biological replicas. Results were presented as fold change value [11].
2.5. Western Blot
Total cell extracts were prepared using lysis buffer containing a cocktail of protease inhibitors
(Carl Roth, Karlsruhe, Germany), as described previously [12]. Proteins were analyzed by Western
blot using chemiluminescence detection method [12]. Primary antibodies were used for detection of β
actin, JAGGED1, PARP1, IKZF3 (all from Santa Cruz, Dallas, TX, USA), HES1, IKZF1, NOTCH1 and
NOTCH1 cleaved (all from Cell Signaling Technology, Danvers, MA, USA). Densitometric analysis
was performed using ImageJ program (NIH, Bethesda, MD, USA).
2.6. Statistical Methods
Data were statistically analyzed using the software package Microsoft Office. A parametric test
was used for comparison of results between control and treated cells. The significance of independent
two-tailed Student’s t-test was set at p-value < 0.05.
3. Results
3.1. Effect of Notch and PARP inhibition on Jurkat, CLL and 697 Cells’ Proliferation
Notch pathway is considered to be one of the main pathways directing cells toward T and not B
lineage and is often deregulated in T cell leukemia. Certain types of leukemia can even be “addicted”
on Notch activity and its abrogation could influence cell proliferation [13]. On the other side, a direct
role of PARP1 in differentiation is still under investigation, but it is known that it can influence the
structure of cell chromatin and modulate transcription factor activity [6,14].
Analysis of Notch signaling in model cell lines showed that this pathway was active in Jurkat
T cells, as well as in B chronic lymphocytic cell line CLL, while in pre B cells 697 was not. These
data could be concluded from the presence of cleaved Notch domain NICD and expression of Notch
downstream target HES1 (Figure 1).
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Figure 1. Characterization of the Notch signaling pathway in leukemic cells. Notch signaling activity 
in T cell line (Jurkat), B chronic lymphocytic cell line (CLL) and B cell precursor leukemia cell line 
(697) was analyzed by Western blot. FL: full-length; NTM: transmembrane/intracellular region; 
ACTB: β-actin. 
Next, we analyzed cell proliferation and cytotoxicity in cells treated with different 
concentrations of PJ-34, the inhibitor of PARP activity [15]. We detected no cell proliferation arrest 
and no significant cytotoxicity in any of three cell lines, except B CLL line showing decreased 
proliferation after six days of treatment with 40 µM PJ-34. In parallel, treatment with 20 µM DAPT 
[16], γ-secretase inhibitor, did not influence cell proliferation in Jurkat cells. Proliferation of 697 and 
CLL cells started to decrease after the fourth day, and was significantly decreased in 697 cells after 
six days of treatment (Figure 2). Viability of all the cell lines was on the control level. 
 
Figure 2. Influence of PJ-34 and DAPT inhibitors on proliferation and viability of leukemic cell lines. 
Jurkat, 697 and CLL cell lines were treated with PARP1 inhibitor PJ-34 (A) and Notch inhibitor DAPT 
(B) every second day, for six days. Total cell number and the fraction of living cells were obtained by 
counting cells stained with Trypan blue dye under the light microscope. The standard deviation of 
the four different counts is displayed. C: control cells; 10 µM, 20 µM, 40 µM, and 50 µM: 
concentrations of the treating agent; * p-value < 0.05. 
Figure 1. Characterization of the Notch signaling pathway in leukemic cells. Notch signaling activity in
T cell line (Jurkat), B chronic lymphocytic cell line (CLL) and B cell precursor leukemia cell line (697) was
analyzed by Western blot. FL: full-length; NTM: transmembrane/intracellular region; ACTB: β-actin.
Next, we analyzed cell proliferation and cytotoxicity in cells treated with different concentrations
of PJ-34, the inhib tor of PARP act vity [15]. We det cted no cell proliferation arrest and no significant
cytotoxicity in any of three cell lines, except B CLL line showing decreased proliferation after six days
of treatment with 40 µM PJ-34. In parallel, treatment with 20 µM DAPT [16], γ-secretase inhibitor,
did not influence cell proliferation in Jurkat cells. Proliferation of 697 and CLL cells started to decrease
after the fourth day, and was significantly decreased in 697 cells after six days of treatment (Figure 2).
Viability of all the cell lines was on the control level.
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Figure 2. Influence of PJ-34 and DAPT inhibitors on proliferation and viability of leukemic cell lines.
Jurkat, 697 and CLL cell lines were treated with PARP1 inhibitor PJ-34 (A) and Notch inhibitor DAPT
(B) every second day, for six days. Total cell number and the fraction of living cells were obtained by
counting cells stained with Trypan blue dye under the light microscope. The standard deviation of the
four different counts is displayed. C: control cells; 10 µM, 20 µM, 40 µM, and 50 µM: concentrations of
the treating agent; * p-value < 0.05.
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3.2. Effect of Notch and PARP Inhibition on Jurkat, CLL and 697 Cells’ mRNA Expression
The expression of a series of genes involved in Notch and PARP pathways was analyzed in Jurkat,
CLL, and 697 cells after one and nine days of treatment with Notch and PARP inhibitors, alone or in
combination, by qRT-PCR (Figure 3).
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in samples treated for 24 h and nine days with Notch inhibitor. Expression of NOTCH1 and 
NOTCH2 receptors showed oscillations in dependence on DAPT treatment after 24 h and nine days. 
c-MYC decreased its expression even after 24 h, and stayed downregulated for nine days of 
treatment with Notch inhibitor. Cells treated with DAPT had also decreased expression of 
JAGGED1, after one and nine days. PARP inhibition similarly affected its expression. PARP1 and 
PARG, coding for an enzyme involved in degradation of polyADPribose chains produced by 
PARP1, had control level expression, after both types of treatment for nine days. We also tested 
expression of IKZF3 and IKZF1, two members of Ikaros transcription factor family, which can 
interfere with NICD complex binding to RBPJ sequence [17]. They did not show any significant 
Figure 3. Influence of Notch and PARP pathways’ inhibition in Jurkat, CLL, and 697 cell lines. Cells
were treated with PARP inhibitor PJ-34 and/or Notch inhibitor DAPT every other day through nine
days, when RNA was isolated and, after reverse transcription, qRT-PCR was performed. Representative
results are shown. Relative expression is presented as a fold change in comparison with untreated
control sample values. As endogenous control gene HPRT expression was used. C: control cells; PJ-34:
cells treated with PJ-34 (10 µM for CLL and Jurkat cells and 40 µM for 697); DAPT: 20 µM DAPT;
PJ-34/DAPT: cells treated with combination of 10 µM PJ-34 and 20 µM DAPT; * p-value < 0.05.
Jurkat cells’ analysis revealed typical decrease of HES1 expression, as being direct Notch target,
in samples treated for 24 h and nine days with Notch inhibitor. Expression of NOTCH1 and NOTCH2
receptors showed oscillations in dependence on DAPT treatment after 24 h and nine days. c-MYC
decreased its expression even after 24 h, and stayed downregulated for nine days of treatment with
Notch inhibitor. Cells treated with DAPT had also decreased expression of JAGGED1, after one
and nine days. PARP inhibition similarly affected its expression. PARP1 and PARG, coding for an
enzyme involved in degradation of polyADPribose chains produced by PARP1, had control level
expression, after both types of treatment for nine days. We also tested expression of IKZF3 and IKZF1,
two members of Ikaros transcription factor family, which can interfere with NICD complex binding to
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RBPJ sequence [17]. They did not show any significant changes in expression 24 h after treatment, but
after nine days of treatment with DAPT IKZF3 expression decreased by ~40%.
CLL cells exprimed Notch pathway molecules, receptors NOTCH1 and NOTCH2 and ligand
JAGGED1, as well as HES1, a downstream Notch target, indicating unusual activity of the pathway.
Inhibition of γ secretase for nine days induced only a small decrease in HES1 and NOTCH1 expression.
Another downstream target, c-MYC, did not show significant differences in its expression after 24-h
treatment, but after nine-day treatment with DAPT, c-MYC expression was decreased to ~50% of control
values. While IKZF3 expression did not significantly changed, nine days of γ-secretase inhibition
induced ~50% decrease in IKZF1 expression. Although it is known that chronic lymphocytic leukemia
cells could have active Notch pathway due to Notch mutation, the inability of HES1 to be inactivated by
DAPT led us to analyze the expression of EBV protein EBNA2. Namely, B chronic leukemia cell lines are
usually produced by EBV immortalization, and EBNA2 can also bind to Notch targeting sequences [18].
As we found EBNA2 expression, we concluded that CLL cells have expression of downstream Notch
target genes caused by EBNA2 binding. Although 24-h treatment caused fluctuations in EBNA2
expression, no significant changes were observed after prolonged treatment with inhibitors. PARP
inhibition increased expression of JAGGED1, Notch ligand by more than two times, when tested in
the samples treated for nine days. Delta-like ligand 1 (DLL1), another Notch ligand, did not show
detectable expression by PCR (data not shown).
We also analyzed 697 cell line, originating form B acute lymphocytic leukemia and showing pre-B
phenotype. These cells did not have active Notch pathway, but, as we observed indirect effects of
γ-secretase inhibition in other cell lines, we treated these cells with PJ and DAPT alone. Expression
of genes involved in Notch and PARP pathways was analyzed, after one and nine days of treatment.
HES1, as Notch downstream target, was not expressed in these cells, and c-MYC expression was
not dependent on its signaling. γ-secretase inhibition decreased IKZF3 expression after nine days of
treatment. PARP inhibition decreased expression of NOTCH1, NOTCH2, PARP1, IKZF3 and IKZF1
after 24 h, but by prolonged treatment most of these effects were lost. PJ-34 also increased expression
of JAGGED1 for nearly two times after nine days of treatment.
3.3. Effect of Notch and PARP Inhibition on Jurkat, CLL and 697 Cells’ Protein Expression
Proteins expressed from genes influenced by PARP and Notch inhibitors were analyzed by
Western blot. Active NOTCH1 pathway and presence of NICD1 were detected in Jurkat cells, absence
of NICD1 and HES1 in 697, and expression of HES1, but absence of NICD in CLL (Figure 1).
Analysis of Jurkat cells treated for nine days with Notch inhibitor showed abrogation of HES1
expression, IKZF1 expression was equal in control and treated cells and IKZF3 was moderately
decreased after treatment. In addition, following mRNA inhibition, expression of JAGGED1 on protein
level was decreased. PARP inhibition did not significantly change the expression of HES1, IKZF3,
IKZF1, and PARP1, and we did not observe decrease in JAGGED1 expression.
In CLL cells, HES1 did not change its expression after nine days of PARP and Notch inhibition.
IKZF1 and IKZF3 levels were lower in DAPT treated cells. PARP expression was similar in untreated
and treated cells and JAGGED1 expression was slightly increased in cells treated with PARP inhibitor
(Figure 4).
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Figure 4. Influence of N tch and PARP pathways’ i hibition on protein expression. T cell line (Jurkat),
B chronic lymphocytic cell line (CLL) and B cell precursor leukemia cell line (697) were treated with
Notch pathway inhibitor DAPT (20 µM) or PARP inhibitor PJ-34 (10 µM) for nine days, when proteins
were isolated and analyzed by Western blot. CTF: C-terminal fragment; ACTB: β-actin.
In 697 cells, HES1 was not exprimed, as expected; IKZF1 was on control level; and IKZF3 showed
decrease in expression after treatment with both, PARP and Notch inhibitors. We could not detect
JAGGED1 increase on the protein level.
4. Discussion
In our experiments, we analyzed changes in a set of genes/proteins involved in PARP and Notch
signaling pathways after long-term treatment of three leukemia cell lines with PARP and Notch inhibitors.
We analyzed T cell line Jurka , k own for active Notch pathway, a pre B leukemia cell line without active
Notch pathway, and a chronic lymphocytic cell line obtained by EBV immortalization of pre B leukemia
cells. The CLL line did not have active NOTCH1 intracellular domain, but showed activity of downstream
Notch target genes. Jurkat ells had a NOTCH1 mutation enabling its constant activation [19].
Analyzing changes in expression in cells treated with γ-secretase inhibitor DAPT, we observed
inhibition of genes known to be Notch downstream targets in cells where typical active Notch pathway
was present in untreate cells. We c uld also expect consequences of inhibition of a series of molecules
which are direct substrates of γ-secretase (around 90 proteins, if expressed). Beside Notch receptors, these
are Delta and Jagged ligands and amyloid precursor protein (e.g., [20]). However, even if their conformation
allows γ-secretase to cut them, it i difficult to predict the effect on the gene expression as the target genes
are regulated through multiple positive and negative feed-backs and promoter chromatin structure.
Jurkat cells present typical cells with active Notch signaling, inhibited by γ-secretase. Already
24 h after pathway inhibition there was a downregulation of Notch target genes such as HES1 and
c-MYC. We also observed inhibition of JAGGED1, Notch ligand, and possible γ-secretase substrate.
Inhibition of Notch signaling did not cause cell arrest and apoptosis and the cells remained
viable. Jurkat cells belong to T-ALL resistant to Notch signaling inhibitors due to PTEN-null genotype.
Namely, PTEN expression in nonmutated cells inhibits survival pathways going through Akt and
PI3K and stops proliferation. Furthermore, its promoter is by feed-back loop regulated by HES1,
a downstream Notch target. In Jurkat and some other T-ALL cells, this pathway is abrogated by PTEN
deficiency and these cells become dependent on Akt survival pathway [21,22].
Another gene downregulated by Notch inhibition is c-MYC. This gene can also be regulated
by several pathways, such as those Akt related. c-MYC was in CLL and Jurkat cells decreased for
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50%. We could suppose that in CLL c-MYC decrease can be connected with the slowing down of
cell proliferation, but in Jurkat cells proliferation was independent of c-MYC expression. Having
other signaling pathways to force proliferation, c-MYC downregulation in proliferating cells is not
uncommon in lymphocyte biology; i.e., similar features are present in some parts of germinative center
of lymph nodes [23]. In addition, Notch and c-MYC could also be connected through regulatory loops
involving microRNA (mostly microRNA 30a) in B and T leukemia [24]. In pre B leukemic cells, IKZF1
and IKZF3 were also found to inhibit proliferation through the decrease of c-MYC expression [25].
JAGGED1 is a Notch ligand whose role in the regulation of Notch pathways is still under
investigation. It was found to increase Notch signaling in lymphomas, through the NOTCH2-HEY1
pathway [26]. In certain tissues reciprocal regulation of Notch pathways was found to be exerted
by DLL1 and JAGGED1 [27]. Recently, it was discovered that JAGGED1 can be cleaved by the same
molecules as NOTCH receptor and that intracellular domain can cause signal transduction in the
host cell, competing with Notch [20]. Thus, being a substrate of γ-secretase, it is possible that DAPT
inhibited its expression in Jurkat cells by feedback signaling.
Prolonged treatment with γ-secretase inhibitor caused changes in expression of not only genes
which were immediately downregulated, but also those of IKZF1 family of transcription factors:
in Jurkat and 697 cells IKZF3 was decreased, and in CLL IKZF1, regardless of the Notch pathway
inhibition. Their role in cell regulation is still widely unknown. It is known that IKZF1 is important
for directing lymphocytes toward T cell line and that its deleted forms could be found in a set of
T-ALL [28]. Ikaros family proteins act as transcription factors and could have a role in a chromatin
remodeling interacting with NuRD complex [29,30]. IKZF1 targets elements similar to RBPJ sequence,
the downstream target of Notch signaling. On its binding sites there is often competition or cooperation
between different transcription factors. It was found that IKZF1 influences the repertoire of Notch
target genes in T cells targeting to RBPJ regulatory sequences [31,32] and Notch signaling loops
antagonize IKZF1 expression in T-ALL. IKZF1 expression was found to be reduced in T-ALL patient
samples with activating Notch pathway mutations. The supposed mechanism is competition for
direct target promoter binding, such as on MYC gene [33]. IKZF1 and IKZF3 are considered tumor
suppressors and their inability to perform their functions are connected with tumor development.
Knockdown of Ikaros reduced B cell differentiation to plasma cells [34]. Recently a new mechanism
was found by which Ikaros takes part in transcription complex with IRF4 and in this way regulates
genes which should be downregulated during plasma cell differentiation [34,35]. IKFZ1 was also found
to repress expression of PI3K pathway genes. These data indicate the role of this family in intricate
signaling loops regulating blood cell differentiation. Possibly, inhibition of a signaling pathway
stimulating proliferation needs to be balanced by inhibition of a tumor suppressor, through their
signaling circuits, to retain viability and proliferation. In addition, as loss of IKFZ1 leads to ineffective
tyrosine kinase inhibitor therapy in certain types of leukemia, the ability of chemotherapeutic to
decrease its expression could have an influence on the final output of anticancer therapy [36].
Changes in Ikaros family members became significant after the prolonged period of γ-secretase
inhibition, indicating indirect and secondary signaling. IKZF1 promoter is extremely complex, having
several distinct modules/enhancers forming regulatory units to upregulate its expression in different
hematopoietic cells or during cell differentiation. These regulatory regions depend on a number of
transcription factors, such as IKZF1, ETS1, c-MYC, RUNX1, etc., and several of them could be involved
in positive and negative signaling loops of Notch signaling [37]. In addition, IKZF1 was also found to
control IKZF3 expression [38].
Considering B cell lines, Notch activation can lead to pre B leukemia cells’ apoptosis [8]. On the
other side, a fraction of B-CLL types can have constitutively active Notch pathway, mainly because of
PEST-domain mutations. It was found that it is crucial for their survival and its abrogation could lead
these cells to apoptosis [39]. Our model CLL line had active Notch signaling but did not show apoptosis
after treatment with Notch inhibitor and only 20% decrease in growth was present after long-term
treatment. Protein analysis showed the absence of NOTCH1 intracellular domain, NICD1, but presence
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of HES1 expression. We found expression of EBNA2, early EBV protein involved in latency type II and
III, being expressed as a consequence of immortalization process. EBNA2 binds to RBPJ sequences in
the genome, competing out Notch intracellular domain [18]. CLL cells showed resistance to γ-secretase
inhibitor acting on upstream levels of Notch signaling. HES1 and c-MYC expression could therefore be
a consequence of EBNA2 binding. EBNA2 levels did not change significantly after DAPT treatment.
PARP1 is a multitasking protein involved in a cellular response on DNA damage as well as in
transcription and differentiation processes. It can modulate the activity of several transcription factors,
either through protein–protein interactions or through parpylation, addition of polyADP-ribose. Being
an inhibitor of PARP activation, PJ-34 can influence only a set of PARP activities in the cell. PARP was
found to be connected with Notch signaling through modification of a complex in which transcription
factor HES1 takes part [7]. Kannan et al. [8] found that Notch signaling in B cell ALL, which led to
growth arrest and apoptosis was regulated by HES1 modulated by PARP1. As HES1 was not exprimed
in 697 cells, PARP inhibition did not significantly influence survival and proliferation of these cells.
In T-ALL and CLL cells, the most prominent effect of PARP1 inhibition was the influence on
JAGGED1 expression. While it was upregulated in both B cell lines, in Jurkat cells, JAGGED1 expression
was decreased. One possibility is that PARP1 modulates both, activation and repression complexes on
the gene promoter, in dependence on the intracellular milieu [7] and the other that PARP1 modulates
different transcription factors present in different cell types, such as NFAT1, NF-κB or others [6,40,41].
PARP1 targets are also SMAD transcription factors, influencing the duration of TGF β signaling, and
JAGGED1 is a known TGF β target [42,43]. On the other side, analysis of TGF β expression after PARP
inhibition revealed downregulation in Jurkat cells after prolonged treatment. In other cell lines, TGF β
expression was not significantly influenced by treatment (data not shown).
Finally, we could conclude that each type of leukemia and leukemia cell line has a unique net
of signaling pathways connected with feedback loops and does not respond to inhibition of certain
pathway in the same way. Jurkat and CLL cells, although having active downstream Notch signaling,
do not respond to Notch signaling inhibitor by cell arrest or apoptosis, although inhibition of upstream
signaling was present. In similar experiments with different types of tumors, certain differentiation
cues did even cause changes in DNA methylation pattern and binding patterns of transcription factors,
but cells re-entered the proliferation cycle when the growth factor was removed. Persistent oncogene
expression made cells resistant to differentiation cues [44]. Although we showed that long-term treatment
could cause changes in expression of signaling molecules, possibly other pro-survival signaling circuits
dominated over Notch pathway, enabling these cells to be resistant to apoptosis and differentiation.
Our results showed that effects of Notch and PARP inhibition, although influencing similar groups
of genes in different cell lines, also greatly depend on the intracellular milieu of each cell line. Therefore,
it would be interesting to analyze primary B and T cells, as well as primary leukemia cells. Similar
experiments have been already done in certain subgroups of these cells. Different Notch inhibitors
were shown to influence early T cell development, as well as decrease cytokine production in activated
T cells [45]. Considering B cells, Notch inhibition did not influence significantly viability of normal
peripheral B lymphocytes but caused depletion in marginal B zone cells in vivo [46]. In primary leukemic
cells, Notch inhibition was cytotoxic for a subgroup of Notch-mutated B and T leukemic cells [39,47].
Effects of PARP inhibition were analyzed in trials testing olaparib, a PARP inhibitor used for cancer
treatment. PARP inhibition on immortalized B lymphocytes did not show decrease in cell viability. At
the molecular level, Martin et al. found that olaparib caused changes in expression of genes involved
in stress response, protein ubiquitination and cell signaling, possibly mediated through regulation of
epigenetic regulator EZH2 and NFAT signaling [48]. These processes were involved in cell differentiation
and cytokine expression. Considering lymphoid tumor cells, PARP inhibition was shown to be cytotoxic
for ATM-deficient cells, in vivo and in vitro [49]. All these data indicate the necessity of getting global
insight into the cellular circuits governing mechanisms involving Notch and PARP in different cell types.
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5. Conclusions
Long-term inhibition of Notch signaling and PARP activity in three leukemic cell lines of B and
T origin did not cause proliferation arrest and apoptosis, but induced changes in expression in a set
of genes. Inhibition of PARP1 caused JAGGED1 expression to change in all three types of observed
lines. The γ-secretase inhibitor influenced the expression of transcription factors from the Ikaros family
regardless of the Notch signaling activity, but depending on the differentiation type of lymphocyte.
Further investigations are needed to explain the mechanisms of these processes, which could have an
influence on chromatin structure and change the cell response on other chemotherapeutics.
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